Introduction
============

Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) that is rapidly and extensively absorbed in the intestine before conversion to 5-FU.[@b1-cmar-10-4517] Severe, life-threatening, and even fatal toxicity has been associated with deficient dihydropyrimidine dehydrogenase (DPYD) activity in patients receiving fluoropyrimidine-based chemotherapy at standard doses.[@b2-cmar-10-4517] Capecitabine-induced adverse reactions include severe hand-foot syndrome, gastrointestinal toxicity, hematological toxicity, and cardiotoxicity.[@b3-cmar-10-4517],[@b4-cmar-10-4517]

Low DPYD activity is partly explained by genetic variability in the *DPYD* gene, which is highly polymorphic.[@b5-cmar-10-4517],[@b6-cmar-10-4517] However, only a few variants (ie, rs3918290 \[*DPYD*\*2A\], rs55886062 \[*DPYD*\*13\], and rs67376798) have been clearly associated with severe toxicity to fluoropyrimidines. In our hospital, genotyping of these three variants is available on request for patients starting fluoropyrimidine therapy and has proved to be cost-effective.[@b7-cmar-10-4517] Nonetheless, this test enables us to avoid only 10%--15% of capecitabine-related severe adverse reactions, thus strongly suggesting that other genetic variants in *DPYD* or in other genes might also be implicated.[@b8-cmar-10-4517] DPYD phenotyping based on the measurement of the enzyme activity in peripheral blood mononuclear cells is another proposed approach to minimize life-threatening toxicity.[@b9-cmar-10-4517] It is yet to be discerned which of these approaches offers the better predictive value and is the most cost-effective to implement or whether a combination of both would be the preferred choice.

Case report
===========

A 79-year-old Caucasian woman was diagnosed with poorly differentiated carcinoma that appeared to have originated in breast tissue. She underwent a second-line chemotherapy based on capecitabine (2 weeks on and 1 week off, total dose of 2,600 mg/day in days 1--14).

After 8 days of treatment, she visited the emergency room with progressive asthenia, grade 1 diarrhea, and grade 1 mucositis and was discharged after parenteral fluid support and intensive treatment with loperamide. Capecitabine was discontinued after 48 hours (cumulative dose 26 g) owing to rapidly increasing toxicity despite oral rehydration and a standard dose of loperamide. The main symptoms were diarrhea (grade 2), nausea (grade 2), odynophagia (grade 2), severe solid dysphagia, painful mucositis (grade 3), and progressive asthenia (grade 2) associated with low-grade fever. She was admitted to hospital immediately for close monitoring with intensive fluid and nutritional support, broad-spectrum antibiotics (piperacillintazobactam, vancomycin, and fluconazole), and pain relievers.

Both hematological toxicity (grade 4 neutropenia and grade 2 thrombocytopenia) and non-hematological toxicity (grade 1 palmar-plantar erythrodysesthesia, grade 2 diarrhea, and grade 3 mucositis) worsened rapidly. Her white blood cell count dropped, reaching a zero nadir at day +16 and remaining unchanged for over 6 days despite treatment with granulocyte colony-stimulating factor. The patient also developed anemia requiring erythrocyte and platelet transfusions. Her platelet nadir started to recover slowly at day +17.

Besides support with blood derivatives, she required third-step analgesia with strong opioids (morphine infusion pump) and intensive nutritional support with parenteral nutrition. The consequences of the severe mucositis and diarrhea resulted in low blood levels of potassium, calcium, phosphate, magnesium, and protein, with significant weight loss (up to 5 kg). In addition, the international normalized ratio was increased, with normal liver transaminases. Hand-foot syndrome progressed more slowly during hospitalization, with progressive, painful swelling and numbness on the palms and soles (up to grade 2), together with progressive alopecia that started 20 days after the withdrawal of capecitabine and lasted for more than 3 months. After 23 days in hospital, the patient was discharged with oral nutritional supplements that were necessary for over 2 months until she could tolerate a normal diet.

DPYD deficiency was suspected as a potential explanation for the life-threatening toxicity that developed after such a short interval of exposure to fluoropyrimidine, in the absence of liver or renal dysfunction and other potential drug interactions. The patient did not receive treatment with fluoropyrimidines again. After two further chemotherapy lines, first cyclophosphamide+ zolendronic acid and later vinorrelbine, the patient died due to disease progression.

A routine genetic *DPYD* test was carried out in our hospital because of the strong suspicion of DPYD deficiency. The three *DPYD* single-nucleotide polymorphisms (SNPs) were genotyped according to the recommendations of the Clinical Pharmacogenetics Implementation Consortium at the time.[@b10-cmar-10-4517] The SNPs were genotyped using real-time PCR and TaqMan probes. None of the three variants were detected. However, the presence of a DPYD deficit continued to be suspected. Therefore, after receiving written informed consent, we performed complete sequencing of the 23 *DPYD* exons. A total of 23 pairs of oligonucleotides ([Table 1](#t1-cmar-10-4517){ref-type="table"}) were used to amplify and sequence *DPYD* exons. We identified two variants in *DPYD* exons, c.1601G\>A (rs1801158, p.Ser534Asn, *DPYD*\*4) and a previously unreported splice site mutation at position 2242+1G\>T, after the end of exon 19 ([Figure 1](#f1-cmar-10-4517){ref-type="fig"}). This variant was most probably affecting splicing as confirmed using Human Splicing Finder v3.1.[@b11-cmar-10-4517]

The effect of this second SNP on the donor splicing site was analyzed. RNA was isolated from peripheral blood mononuclear cells and processed to cDNA. A cDNA fragment from exon 18--20 was amplified using specific primers (forward \[5′-TTAAAATCTGATGGCACACCTTG\] and reverse \[5′-TGCTTTTCAGATAAAGCAGGGCT\]). PCR product sizes were estimated using electrophoresis. Sequencing of PCR products revealed skipping of exon 19 of *DPYD* in the patient's mRNA ([Figure 2](#f2-cmar-10-4517){ref-type="fig"}). DPYD generated a truncated protein of 795 amino acids lacking the correct sequence from 767 to the end (1025) ([Figure 3](#f3-cmar-10-4517){ref-type="fig"}). This region is considered essential for the functionality of the protein because it is part of the pyrimidine-binding domain (from 525 to 847).[@b12-cmar-10-4517]

Due to the interest of this novel discovery and its potential clinical implications, genotyping of the mutation was later performed in the patient's offspring: one son, one daughter, and one granddaughter (a daughter descendant). For this purpose, a TaqMan probe was synthesized for 2242+1G\>T. All individuals carried the 2242+1G\>T mutation in heterozygosis. None of them presented the *DPYD*\* four allele.

DPYD phenotype assessment was performed by pretreatment measurement of plasma uracil (U) and dihydrouracil (UH2) in the descendants.[@b13-cmar-10-4517] Unfortunately, we were not able to analyze a sample from the original patient because at the time this analysis was performed, she was already deceased.

Two samples showed DPYD deficiency according to established criteria (uracil concentration \>16 ng/mL and/or UH2/U ratio \<6). The other sample showed values that were close to the limit but within the normal activity range. Phenotyping results are shown in [Table 2](#t2-cmar-10-4517){ref-type="table"}.

A TaqMan probe was synthesized for genotyping of 2242+1G\>T in a cohort of 487 anonymous DNA samples from colorectal cancer patients (mainly Caucasians from Iberian ancestry). None of the samples analyzed, except that of the present case, carried this mutation, indicating that it is a rare variant in our setting.

Discussion
==========

The severe toxicity can be explained by the presence of the variant c.2242+1G\>T, which generates shorter mRNA and protein, thus rendering a non-functional DPYD protein that lacks a sequence in the pyrimidine-binding domain ([Figure 3](#f3-cmar-10-4517){ref-type="fig"}). The SNP is just located in the first nucleotide after the end of exon 19. Other *DPYD* variants affecting donor splicing sites have also demonstrated skipping of the corresponding exon[@b12-cmar-10-4517],[@b14-cmar-10-4517] or generation of an in-frame insertion of small fragments causing severe and occasionally fatal adverse reactions to fluoropyrimidine.[@b15-cmar-10-4517]

In this patient, a non-synonymous variant, c.1601G\>A (rs1801158, p.Ser534Asn), was also observed. This variant defines the *DPYD*\* four allele and decreases protein activity by 20%. However, although this allele has previously been related to the risk of fluoropyrimidine-induced toxicity,[@b16-cmar-10-4517],[@b17-cmar-10-4517] a recent meta-analysis did not find any significant association between c.1601G\>A and severe fluoropyrimidine-induced toxicity.[@b18-cmar-10-4517] The DPYD deficiency observed in two out of three members of the family carrying the c.2242+1G\>T mutation supports the effect of this variant on the fluoropyrimidine metabolism. The fact that none of them presented variant c.1601G\>A further backs the theory that this new variant may be responsible for the descent in activity. As previously described, individuals carrying one functional and one nonfunctional allele of *DPYD* are likely to display a partial deficiency with 1.5\<UH2/U\<6[@b9-cmar-10-4517]. The third family member carrying this mutation showed a UH2/U ratio within the normal activity range, although close to the limit (6.6). This could be explained by factors not studied, such as copy number variants increasing the activity of the functional allele, or additional mutations in the other members.

The frequency of the *DPYD* variant c.2242+1G\>T variant is lower than 0.002% in our setting, which suggests that it is a rare variant and its inclusion in our routine genotyping tests would not significantly increase their predictive value. Testing for this variant in other populations (since our sample is mainly integrated by Caucasian individuals of Iberian ancestry) would be very interesting as it could help to investigate its possible origins. This is definitely a line of investigation to be pursued in future works.

Conclusion
==========

We consider the newly described variant 2242+1G\>T in *DPYD* to be the most probable cause of very severe toxicity following the first cycle of treatment with capecitabine in a patient with breast cancer. DPYD phenotyping in patient's offspring carrying the mutation showed decreased enzymatic activity, further supporting this conclusion. Whole DPYD sequencing is an interesting approach for the identification of causal variants in patients with suspected DPYD deficiency in whom routine *DPYD* tests yield negative results.
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![Sequence electropherogram of the 2242+1G\>T variant. Blue, dCTP; green, dATP; black, dGTP; red, dTTP.\
**Abbreviations:** dATP, deoxyadenosine triphosphate; dCTP, deoxycytidine triphosphate; dGTP, deoxyguanosine triphosphate; DPYD, dihydropyrimidine dehydrogenase; dTTP, deoxythymidine triphosphate.](cmar-10-4517Fig1){#f1-cmar-10-4517}

![Exon skipping sequence.\
**Notes:** Left: Electrophoresis of amplified cDNA from peripheral blood mononuclear cells of a patient carrying the 2242+1G\>T variant. Right, upper: Graphic representation of skipping of exon 19. Right, lower: Sequence electropherogram using the primer Ex18F. A double sequence is observed for 85 nucleotides corresponding to overlapping of exons 19 and 20.](cmar-10-4517Fig2){#f2-cmar-10-4517}

![Structures of wild-type DPYD and truncated DPYD.\
**Notes:** The interpretation of mutation effect and the molecular modeling were performed by using Deep View Swiss-PDB viewer and Tasser. (**A**) Modeling of wild-type DPYD; (**B**) modeling of truncated DPYD.](cmar-10-4517Fig3){#f3-cmar-10-4517}

###### 

List of primers used for *DPYD* exon sequencing

  Exon number     Forward                     Reverse                      Fragment size
  --------------- --------------------------- ---------------------------- ---------------
  EXON 1          ACTTGGCTCTCTGGCTGGAGCTT     AAACTTTCCCGCGTCTCTCACTC      234
  EXON 2          TTAGCCAGGTGTGGTAGCGTAC      TGCCTTACAATGTGTGGAGTG        410
  EXON 3          TGAGACTTCTGTGACAGCTGTA      CCTCAAGGGAAGTCTCTCCAC        442
  EXON 4          GGAGTGCCAAAGATGAAACACA      TGGATTTGCTAAGACAAGCTG        362
  EXON 5          TCCTATGTGTCAAATACTCTGCT     TGGGTATCAACAGAGCACCA         444
  EXON 6          AGGAGGCATGACTCTAGAAAGG      CCATTAAAAGAAATATTCACAGGGCT   719
  EXON 7          AGAATGTAGATGTCCTCATGCA      TGCATGACATTTGCTGTTAATC       331
  EXON 8          AGCCCTTAATAGAACATGTTCCT     TGAAGGCAGTCATTCTTCTGG        374
  EXON 9          TGCTTACAGATGTTTTCCTCT       ACAATGTGCTGCTGAGCTTG         324
  EXON 10         TGGAAAACTGCAAGATGCAA        AGCCCTTGAGTATTGACAAAG        312
  EXON 11         TGGTGAAAGAAAAAGCTGCAT       GTTCTTTTCAATACTTGCCACT       548
  EXON 12         TGTGTTGTTAACTCCAATATTTCGT   TCAAGCATCCTCCCGCTT           621
  EXON 13         TTCGGATGCTGTGTTGAAGT        AATGTGTAATGATAGGTCTTGTCAAA   443
  EXON 14         GCTTTTCTTTGTCAAAAGGAGAC     AGCTTCACATTGTGTGGGTT         409
  EXON 15         TAATTCCAAAGCCCCAAATG        TTTCTCATGGCAGCTCTTTATTT      346
  EXON 16         TCAACGGTGAAAGCCTATTG        AGCTTCCCTCATTTTCCACT         318
  EXON 17         TTTGTCTTGCACGTCTCCAG        AGGATCTTGTGTTTCCAGATCA       437
  EXON 18         TGAGAAAGTAAAGTTGTGGTAATT    GGGATCATAAAGGGCACAAA         423
  EXON 19         TCCAGTGACGCTGTCATCA         ACAGGACAGGAAATAAACCTCA       434
  EXON 20         AGACGGCTACTGATCCATCA        TCTGAAATAGAAACCAAGGCTGA      375
  EXON 21         CCCATTTTTCTCTTCTCTGAGC      ATGCATGCTTGCCAGTGT           423
  EXON 22         TCTTTCAGAAGACAAACATCTAAGC   CAGAAAATGCTTTCTGCCGTA        402
  EXON 23         ACGCTAAAATGGGGACATTG        ACATAAGACAACTGGCAGTG         517
  EXON SKIPPING   TTAAAATCTGATGGCACACCTTG     TGCTTTTCAGATAAAGCAGGGCT      

###### 

DPYD phenotyping results

  UH2 concentration, ng/mL   U concentration, ng/mL   UH2/U concentration ratio   Activity[a](#tfn1-cmar-10-4517){ref-type="table-fn"}
  -------------------------- ------------------------ --------------------------- ------------------------------------------------------
  89.32                      13.47                    6.6                         Normal
  85.16                      24.13                    3.5                         Deficient
  47.19                      18.45                    2.6                         Deficient

**Notes:**

Criteria for activity deficiency: uracil concentration \>16 ng/mL and/or UH2/U ratio \<6.

**Abbreviations:** UH2, dihydrouracil; U, uracil.

[^1]: These authors contributed equally to this work
